A smoking cessation smartphone app that delivers real-time ‘context aware’ behavioural support: the Quit Sense feasibility RCT

Felix Naughton,1* Aimie Hope,1 Chloë Siegele-Brown,2 Kelly Grant,3 Caitlin Notley,4 Antony Colles,3 Claire West,3 Cecilia Mascolo,2 Tim Coleman,5 Garry Barton,3 Lee Shepstone,3 Toby Prevost,6 Stephen Sutton,7 David Crane,8 Felix Greaves9 and Juliet High3

1Behavioural and Implementation Science Group, School of Health Sciences, University of East Anglia, Norwich, UK
2Department of Computer Science and Technology, University of Cambridge, Cambridge, UK
3Norwich Clinical Trials Unit, University of East Anglia, Norwich, UK
4Addiction Research Group, Norwich Medical School, University of East Anglia, Norwich, UK
5Division of Primary Care, University of Nottingham, Nottingham, UK
6Nightingale-Saunders Clinical Trials and Epidemiology Unit, Kings College London, London, UK
7Behavioural Science Group, University of Cambridge, Cambridge, UK
8Department of Behavioural Science and Health, University College London, London, UK
9Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK

*Corresponding author  f.naughton@uea.ac.uk

This report contains transcripts of interviews conducted in the course of the research, or similar, and contains language which may offend some readers.
Scientific summary

A smoking cessation smartphone app that delivers real-time 'context aware' behavioural support: the Quit Sense feasibility RCT

Public Health Research 2024; Vol. 12: No. 4
DOI: 10.3310/KQYT5412

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Three million UK smokers attempt to stop smoking each year, but over 80% relapse. A lapse (any smoking) early on in a quit attempt is strongly associated with subsequent relapse back to smoking. Approximately half of all lapses are due to environmental smoking cues which can elicit cravings to smoke, such as the presence of cigarettes or being in a location which a smoker associates with smoking. Few interventions are effective at targeting cue-induced cravings. Smokers are more likely to prevent lapses if they better understand their smoking cues and use lapse prevention strategies, such as controlled deep breathing or avoiding other smokers, to combat these. This would likely help them avoid or cope with cue-induced cravings, but smokers typically lack skills in applying these effectively. If smokers trying to quit used effective lapse prevention strategies, this would very likely increase their chances of success.

With patient and public involvement, we developed, refined and piloted a theory-guided Just-In-Time Adaptive Intervention smartphone app called Quit Sense that provides support to help smokers manage environmental cues to smoke as they arise. Pilot studies have shown that Quit Sense can provide ‘in the moment’ support to smokers, including lapse prevention strategies, and that users will engage with the app and find it acceptable. As Quit Sense is such a novel intervention, before a ‘definitive’ randomised controlled trial (RCT) can be conducted to test effectiveness, it is important to first undertake a RCT to establish whether such a study might be feasible.

Objectives

The main objective was to conduct a feasibility RCT of Quit Sense to inform a definitive effectiveness trial, by estimating:

1. completion rates for the anticipated primary outcome for a full trial (6-month self-reported abstinence with biochemical validation, based on the Russell standard);
2. usual care arm cessation rate;
3. cost of recruitment using online advertising;
4. rates of app installation, use and acceptability;
5. completion of smoking cessation-related resource use and quality-of-life data;
6. intervention effect on anticipated primary outcome;
7. intervention effect on hypothesised mechanisms of action of app at 6 weeks post enrolment;
8. participant views of the app, as part of a qualitative process evaluation.

Design

A parallel, two-arm RCT with an embedded qualitative interview process evaluation was undertaken. The evaluation included a preliminary cost-effectiveness analysis and a nested randomised study [Study Within A Trial (SWAT)] assessing the effects of different financial incentives on 6-month follow-up rates.

Setting

The study setting was online and trial procedures were primarily automated.

Participants

Participants were recruited via online adverts on Google search, Facebook and Instagram, screened for eligibility on the study website and enrolled if they were regular smokers, aged 16 years and above, were willing to make a quit attempt and owned an Android smartphone.
**Interventions**

After completing the baseline questionnaire participants were then randomly allocated to a ‘usual care’ arm (text message referral to NHS SmokeFree website) or a ‘usual care’ plus Quit Sense arm, via a text message invitation to install the Quit Sense app. The Quit Sense app required users to set a quit date and then, leading up to their quit date, alongside other support features, invited them to report their smoking in real time and indicate the presence of key environmental smoking cues using a smoking behaviour logging tool. Once their quit date arrived, the app used location sensing and what it had learnt about the individual’s smoking behaviour to tailor the timing and content of support messages when they spent time in self-identified high-risk locations. The support and advice aimed to help smokers learn about their smoking behaviour, prepare for their quit attempt and promoted the use of effective lapse prevention strategies during their quit attempt.

**Main outcomes measures**

All participants were contacted at 6-week and 6-month follow-up. This was done initially by text message with an embedded link to the follow-up questionnaires or, if no response, manually by telephone. As part of a SWAT, participants underwent secondary randomisation to receive either a £10 or £20 incentive for completion of the 6-month questionnaire.

Four progression criteria and corresponding thresholds for seeking to undertake a definitive trial were set a priori. Criteria were met if each threshold was included in or lower than the 95% confidence interval (CI) of the estimate. Trial measures included health economic and outcome data completion rates (progression criterion #1 threshold: ≥70%), including biochemical validation rates (progression criterion #2 threshold: ≥70%), recruitment costs, app installation (progression criterion #3 threshold: ≥70%) and engagement rates (progression criterion #4 threshold: ≥60%), the app’s effect on biochemically verified abstinence at 6 months (anticipated primary outcome of definitive trial) and hypothesised mechanisms of action. The qualitative process evaluation sought to identify participants’ views of the trial and the Quit Sense app. The protocol and statistical and health economics analysis plan were pre-specified and published (open access).

**Results**

Of the people screened (N = 323), 299 (93%) were eligible and 209 (65% of screened) were consented and randomised either to the usual care arm (n = 105) or to the Quit Sense arm (n = 104). Completion of self-reported smoking questions was 71% (149/209; 95% CI 65% to 77%) and 77% (160/209; 95% CI 71% to 82%) at 6 weeks and 6 months, respectively, and at 6 months 70% provided both cessation support resource use data and EuroQol-5 Dimensions five level (EQ-5D-5L) data. Among those self-reporting abstinence at 6 months follow-up, 39% (95% CI 24% to 54%) returned a viable sample for biochemical verification, although return rates were higher in the Quit Sense than the usual care arm (52% vs. 19%). Online recruitment was completed successfully within the planned 6-week period, split into two campaigns, with a per-participant cost of £19.20, split into advert (£5.82) and running costs (£13.38). In the Quit Sense arm, 75% (95% CI 67% to 83%) of participants installed the app and, of these, 100% set a quit date within the app and 51% (95% CI 39% to 63%) engaged with it for more than 1 week.

At final follow-up, the rate of 6-month biochemically verified sustained abstinence, which we anticipated would be used as a primary outcome in a future study, was 11.5% (12/104) in the Quit Sense arm and 2.9% (3/105) in the usual care arm (estimated effect size: adjusted odds ratio = 4.57, 95% CI 1.23 to 16.94). Similar effects were observed for biochemically verified secondary abstinence outcomes at 6-month follow-up and sensitivity analyses. Effect sizes were smaller and non-significant for self-report only abstinence and there was no evidence of a between-arm difference in abstinence at 6-week follow-up. Participants in the Quit Sense arm had higher rates of lapse avoidance in the first 2 weeks of their quit attempt or post enrolment compared to usual care though this was not statistically significant (29.6% vs. 19.2%; p = 0.14). There was no evidence of between-arm differences in hypothesised mechanisms of action of the app, including the mean frequency of lapse prevention strategy use [mean
difference (MD) −0.07; \( p = 0.46 \), smoking cessation self-efficacy (MD 0.18; \( p = 0.39 \)), strength (\( p = 0.23 \)) and frequency (\( p = 0.83 \)) of urges to smoke or the Wisconsin Inventory of Smoking Dependence Motives subscales of automaticity (\( p = 0.51 \)) and associative processes (\( p = 0.58 \)).

The qualitative process evaluation identified several potential pathways to abstinence among Quit Sense arm participants. Interviewed participants reported finding the insights gained from engaging with the smoking behaviour learning tool before their quit attempt started particularly valuable. They reported that this reinforced their commitment to quit, helped them better understand the drivers of their smoking behaviour and challenged the need for them to smoke. Some also reported finding regular and location-specific support messages encouraging and motivational and that this reinforced the goal of quitting and made them feel equipped when they spent time in locations that they used to smoke in. Participants highlighted several factors which led to disengagement with the app, including relapse, no longer feeling they needed support, not finding the app met their needs and technical issues. Participants also provided suggestions for app improvement relating to logging smoking, adding gamification elements and improved support triggering. Interviewed participants from both arms highlighted how COVID-19 measures had affected their smoking behaviour and restricted the time they spent outside of their home, which would have had implications for location-based cessation support.

In terms of the main cost-drivers, e-cigarettes/vaporisers and nicotine replacement therapy accounted for more than 70% of the total non-intervention costs. The total intervention cost (recruitment advertising and maintaining the Quit Sense app) was estimated to be £28.51 per participant. In both groups, the mean EQ-5D-5L score at both 6-week and 6-month follow-up was lower than that at baseline. A preliminary cost-effectiveness analysis using EQ-5D-5L score as the outcome estimated that the intervention was both more costly and less effective, compared to standard care, though there was no significant difference in cost or effect between the two groups.

The SWAT analysis indicated that increasing the incentive for completing follow-up from £10 to £20 did not increase response rates at 6 months (74% vs. 79%; \( p = 0.36 \)) but did reduce the proportion of participants requiring manual follow-up (62% vs. 46%; \( p = 0.018 \)) and the median response time to responding (15 days vs. 7 days; \( p = 0.016 \)).

**Conclusions**

The Quit Sense RCT design and procedures demonstrated feasibility and generated preliminary efficacy evidence of the app on abstinence at 6-month follow-up, although how the app may achieve this is not clear. Three out of the four pre-specified feasibility progression criteria for moving to a definitive trial – completion rate of self-reported abstinence at final follow-up and the rate of Quit Sense installation and engagement – were met. The return of saliva samples among quitters was lower than anticipated, though this can likely be increased in a future trial through increased incentivisation and enhanced procedures. Progression to a definitive trial is warranted.

**Trial registration**

This trial is registered as ISRCTN12326962.

**Funding**

This award was funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme (NIHR award ref: 17/92/31) and is published in full in Public Health Research; Vol. 12, No. 4. See the NIHR Funding and Awards website for further award information.
Public Health Research

ISSN 2050-439X (Online)

A list of Journals Library editors can be found on the NIHR Journals Library website.

Public Health Research (PHR) was launched in 2013 and is indexed by Europe PMC, NCBI Bookshelf, DOAJ, INAHHTA, Ulrichsweb™ (ProQuest LLC, Ann Arbor, MI, USA) and MEDLINE.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PHR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/phr.

Criteria for inclusion in the Public Health Research journal

Manuscripts are published in Public Health Research (PHR) if (1) they have resulted from work for the PHR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Public Health Research are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

PHR programme

The Public Health Research (PHR) programme, part of the National Institute for Health and Care Research (NIHR), is the leading UK funder of public health research, evaluating public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-NHS interventions intended to improve the health of the public and reduce inequalities in health. The scope of the programme is multi-disciplinary and broad, covering a range of interventions that improve public health.

For more information about the PHR programme please visit the website: https://www.nihr.ac.uk/explore-nihr/funding-programmes/public-health-research.htm

This manuscript

The research reported in this issue of the journal was funded by the PHR programme as project number 17/92/31. The contractual start date was in June 2019. The final report began editorial review in April 2022 and was accepted for publication in January 2023. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PHR editors and production house have tried to ensure the accuracy of the authors' manuscript and would like to thank the reviewers for their constructive comments on the final manuscript document. However, they do not accept liability for damages or losses arising from material published in this manuscript.

This manuscript presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the PHR programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the PHR programme or the Department of Health and Social Care.

Copyright © 2024 Naughton et al. This work was produced by Naughton et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.

For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Newgen Digitalworks Pvt Ltd, Chennai, India (www.newgen.co).